In our previous paper, we reported that the ALK I1171S + G1269A compound mutant was sensitive to the second-generation ALK-TKIs ceritinib and brigatinib, and tumor regression was achieved in this patient after ceritinib treatment. This evidence concerns the gene ALK and neoplasm.